Regeneron And Lilly Are Back With Better COVID-19 Antibody Data – But Still Face Medical Skepticism

New Variants Also Make SARS-CoV2 A Moving Target

 
• By Andrew McConaghie

After disappointing initially, Lilly and Regeneron are back with compelling data for their monoclonal antibody products, but still face challenges from new COVID-19 variants and medical skepticism.

Hospital Covid patient
New data suggests the antibody therapies can have a big impact in preventing infection, or preventing at-risk individuals being hospitalized with severe COVID-19. • Source: Getty Images

More from Business

More from Scrip